Bloomberg "Anywhere" Remote Login Bloomberg "Terminal" Request a Demo

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last kr628.00 DKK
Change Today +25.00 / 4.15%
Volume 506.8K
As of 11:06 AM 09/3/15 All times are local (Market data is delayed by at least 15 minutes).

genmab a/s (GEN) Snapshot

Open
kr614.00
Previous Close
kr603.00
Day High
kr636.50
Day Low
kr612.00
52 Week High
07/20/15 - kr693.50
52 Week Low
10/16/14 - kr212.40
Market Cap
37.3B
Average Volume 10 Days
507.7K
EPS TTM
kr8.11
Shares Outstanding
59.3M
EX-Date
--
P/E TM
77.4x
Dividend
--
Dividend Yield
--
Current Stock Chart for GENMAB A/S (GEN)

Related News

No related news articles were found.

genmab a/s (GEN) Related Businessweek News

No Related Businessweek News Found

genmab a/s (GEN) Details

Genmab A/S, a biotechnology company, develops human antibody therapeutics for the treatment of cancer in Denmark, the Netherlands, the United States, and internationally. The company markets Ofatumumab, a human monoclonal antibody for the treatment of chronic lymphocytic leukemia. Its products under development include Ofatumumab that is in Phase III clinical studies to treat follicular lymphoma and pemphigus vulgaris; and Phase II clinical studies for the treatment of relapsing-remitting multiple sclerosis, as well as Daratumumab, a CD38 monoclonal antibody that is in Phase III clinical studies to treat multiple myeloma. The company’s products under development also comprises HuMax-TF-ADC, an antibody-drug conjugate (ADC), which is in Phase I clinical studies for the treatment of solid tumors; and Teprotumumab, a human antibody that is in Phase II clinical studies for active thyroid eye disease, as well as in Phase I clinical studies for diabetic macular edema. In addition, it has approximately 20 active pre-clinical pipeline programs, including naked antibodies, immune effector function enhanced antibodies, bispecific antibodies, and ADCs. Genmab A/S was founded in 1999 and is based in Copenhagen, Denmark.

179 Employees
Last Reported Date: 08/11/15
Founded in 1999

genmab a/s (GEN) Top Compensated Officers

Co-Founder, Chief Executive Officer and Presi...
Total Annual Compensation: kr11.0M
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: kr5.2M
Compensation as of Fiscal Year 2014.

genmab a/s (GEN) Key Developments

Genmab A/S Enters an Agreement to Grant Novo Nordisk Commercial Licenses

Genmab A/S announced it has entered an agreement to grant Novo Nordisk commercial licenses to use the DuoBody technology platform to create and develop bispecific antibody candidates for two therapeutic programs. The bispecific antibodies will target a disease area outside of cancer therapeutics. Under the terms of the agreement, Genmab will receive an upfront payment of USD 2 million from Novo Nordisk. After an initial period of exclusivity for the two target combinations, Novo Nordisk has an option to maintain exclusivity or take the licenses forward on a non-exclusive basis. Genmab is entitled to potential development, regulatory and sales milestones of up to approximately USD 250 million for each exclusive license, or approximately USD 200 million for each non-exclusive license. In addition, Genmab will be entitled to single-digit royalties on sales of any commercialized products.

Genmab A/S Reports Unaudited Earnings Results for the Second Quarter and First Half of 2015; Reaffirms Earnings Guidance for the Full Year of 2015

Genmab A/S reported unaudited earnings results for the second quarter and first half of 2015. For the quarter, the company reported revenue of DKK 173,842 million against DKK 115,988 million a year ago. Operating result was DKK 39,417 million against loss of DKK 31,710 million a year ago. Net result before tax was DKK 16,489 million against loss of DKK 26,203 million a year ago. Net result was DKK 16,489 million or DKK 0.27 per diluted share against loss of DKK 26,150 million or DKK 0.46 per diluted share a year ago. Cash outflow from operating activities was DKK 23,039 million against inflow of DKK 51,960 million a year ago. For the half year, the company reported revenue of DKK 280,620 million against DKK 363,061 million a year ago. The decrease of DKK 82 million or 23% was mainly driven by lower milestone revenue under the daratumumab collaboration with Janssen. Operating result was DKK 212,357 million against DKK 64,640 million a year ago. The improvement of DKK 147 million was driven by the income from reversal of the ofatumumab funding liability of DKK 176 million combined with lower expenses, which were partly offset by decreased revenue. Net result before tax was DKK 233,793 million against DKK 73,598 million a year ago. Net result was DKK 233,779 million or DKK 3.88 per diluted share against DKK 72,351 million or DKK 1.27 per diluted share a year ago. Cash outflow from operating activities was DKK 78,438 million against inflow of DKK 31,623 million a year ago. Investments in intangible assets were DKK 113,070 million. Investments in tangible assets were DKK 4,333 million against DKK 5,779 million a year ago. The company expects revenue to be in the range of DKK 650 million to DKK 725 million. The company’s projected revenue for 2015 consists primarily of non-cash amortization of deferred revenue totaling DKK 285 million, daratumumab milestones and royalties on sales of Arzerra. Operating income is expected to be in the range of DKK 200 million to DKK 275 million.

Genmab A/S - Special Call

Q&A Session with CEO

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
GEN:DC kr628.00 DKK +25.00

GEN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Ablynx NV €12.43 EUR -0.20
arGEN-X BV €10.24 EUR -0.06
MorphoSys AG €62.67 EUR +0.76
Seattle Genetics Inc $39.33 USD -0.90
XOMA Corp $0.79 USD -0.0491
View Industry Companies
 

Industry Analysis

GEN

Industry Average

Valuation GEN Industry Range
Price/Earnings 77.3x
Price/Sales 46.6x
Price/Book 12.9x
Price/Cash Flow 77.9x
TEV/Sales 43.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact GENMAB A/S, please visit www.genmab.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.